A new oral drug called daraxonrasib has shown remarkable results in treating previously treated metastatic pancreatic cancer. In the RASolute 302 phase III trial, patients taking daraxonrasib lived a median of 13.2 months compared to 6.6 months for those on standard chemotherapy — a doubling of survival. The drug works by blocking RAS signaling, a pathway mutated in over 90% of pancreatic cancers that has historically been considered undruggable. Presented at ASCO 2026 and published in the New England Journal of Medicine, these findings represent the first meaningful advance in second-line pancreatic cancer treatment in years. The FDA has already authorized an expanded access program, giving eligible patients early access while full approval is pursued.
